22.90
-0.36(-1.55%)
Currency In USD
| Previous Close | 23.26 |
| Open | 23.26 |
| Day High | 23.26 |
| Day Low | 22.51 |
| 52-Week High | 29.05 |
| 52-Week Low | 14.4 |
| Volume | 754,544 |
| Average Volume | 1.22M |
| Market Cap | 1.52B |
| PE | -7.74 |
| EPS | -2.96 |
| Moving Average 50 Days | 25.42 |
| Moving Average 200 Days | 22.08 |
| Change | -0.36 |
If you invested $1000 in Celldex Therapeutics, Inc. (CLDX) 10 years ago, it would be worth $98.75 as of November 10, 2025 at a share price of $22.9. Whereas If you bought $1000 worth of Celldex Therapeutics, Inc. (CLDX) shares 5 years ago, it would be worth $1,174.96 as of November 10, 2025 at a share price of $22.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celldex to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 07, 2025 1:01 PM GMT
HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference on Tues
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)All primary and secondary endpoints met with high statistical significance at 12 weeks and sus
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab’s ability to improve urticaria control from the Company’s recently completed Phase 2